Join the 200th Anniversary Celebration

Original Article

Fertility in Men Exposed Prenatally to Diethylstilbestrol

Allen J. Wilcox, M.D., Ph.D., Donna D. Baird, Ph.D., Clarice R. Weinberg, Ph.D., Paige P. Hornsby, Ph.D., and Arthur L. Herbst, M.D.

N Engl J Med 1995; 332:1411-1416May 25, 1995

Abstract

Background

Prenatal exposure to diethylstilbestrol causes infertility in male mice and has been associated with malformations of the genital tract in men. However, little is known about the fertility of men who have been exposed prenatally to diethylstilbestrol.

Methods

In 1950 through 1952, 1646 pregnant women were enrolled in a randomized, placebo-controlled clinical trial of diethylstilbestrol at Chicago Lying-in Hospital. We interviewed men who were born to the women during that study about their fertility.

Results

Four decades after their birth, we were able to trace 548 of the surviving sons (68 percent). Ninety percent consented to be interviewed (253 who had been exposed to diethylstilbestrol in utero and 241 who had not been exposed). Congenital malformations of the genitalia were reported three times as often by the diethylstilbestrol-exposed men as by the sons of the women in the placebo group. Within the exposed group, malformations were reported twice as often among those exposed to diethylstilbestrol before the 11th week of gestation as among those exposed later (P = 0.05). Men with genital malformations were nonetheless as fertile as other men. The diethylstilbestrol-exposed men (with or without genital malformations) had no impairment of fertility by any measure, including whether they had ever impregnated a woman, age at the birth of their first child, average number of children, medical diagnosis of a fertility problem, or length of time to conception in the most recent pregnancy of the female partner. Finally, diethylstilbestrol-exposed men had no impairment of sexual function, as indicated, for example, by the frequency of intercourse or reported episodes of decreased libido.

Conclusions

High doses of diethylstilbestrol did not lead to impairment of fertility or sexual function in adult men who had been exposed to the drug in utero.

Media in This Article

Figure 1Cumulative Probability of Conception per Menstrual Cycle for 119 Couples in Which the Man Was Exposed Prenatally to Diethylstilbestrol and 104 Couples in Which the Man Was Unexposed.
Table 1Follow-up Status of the University of Chicago Cohort of Males Exposed Prenatally to Diethylstilbestrol and Unexposed Males, Born in 1951 or 1952.
Article

Diethylstilbestrol is an orally active synthetic estrogen that for many years was thought to prevent complications of pregnancy. Between the late 1940s and the early 1970s, diethylstilbestrol was prescribed for 2 million to 3 million women in the United States during pregnancy.1 In 1971, diethylstilbestrol was found to be associated with the development of clear-cell adenocarcinoma of the vagina and cervix in young women whose mothers had been given diethylstilbestrol during pregnancy.2 The use of diethylstilbestrol in pregnancy was subsequently banned. Since then, women exposed prenatally to diethylstilbestrol have been found to have an increased risk of reproductive difficulties, including infertility, miscarriage, preterm delivery, and fetal or infant death.1,3,4

At least 1 million men in the United States from 30 to 45 years of age were exposed prenatally to diethylstilbestrol.1 The effects of the drug on their ability to reproduce are unknown. Male rodents exposed prenatally to diethylstilbestrol have an excess prevalence of malformations of the genitalia and infertility.5-7 In men, an excess rate of minor malformations of the genitalia has been associated with prenatal exposure to diethylstilbestrol.8 Fertility problems in men have been suspected,8-10 but the evidence has been inconclusive.

In the early 1950s, a randomized clinical trial of diethylstilbestrol during pregnancy was carried out at the University of Chicago.11 We traced and interviewed men whose mothers participated in that trial and compared the fertility of men who were exposed to diethylstilbestrol prenatally with the fertility of men whose mothers received the placebo.

Methods

In 1950 through 1952, Dieckmann and his colleagues at Chicago Lying-in Hospital conducted a clinical trial of the efficacy of diethylstilbestrol in preventing complications of pregnancy.11 Pregnant women were invited to enroll in this double-blind, placebo-controlled study at their first prenatal visit. The women were randomly assigned to the treatment or placebo group. Women in the treatment group received daily doses of diethylstilbestrol that increased gradually from 5 mg at the 7th week of pregnancy to 150 mg at the 34th and 35th weeks. To verify compliance, phenol red was added to all pills and monitored in the women's urine.

Women were enrolled no later than the 20th week of pregnancy; those in the treatment group received a mean total dose of 12,200 mg of diethylstilbestrol. Since the highest doses were administered late in pregnancy, the stage of pregnancy at which women entered the study had little influence on the total dose: 95 percent of the women in the treatment group received between 11,500 mg and 12,600 mg of diethylstilbestrol.

A total of 848 male babies were born during the original study (Table 1Table 1Follow-up Status of the University of Chicago Cohort of Males Exposed Prenatally to Diethylstilbestrol and Unexposed Males, Born in 1951 or 1952.). Two decades later, when diethylstilbestrol had been identified as a transplacental carcinogen, the University of Chicago attempted to trace all participants and their offspring. Of the 827 sons who survived infancy, 693 were found. Interviews and clinical examinations of 615 of these men were carried out between 1974 and 1976.12 No further contact was made with the men until 1991, when we sought their participation in this study. Our research protocol was approved by the institutional review boards of the National Institute of Environmental Health Sciences and the University of Chicago.

We were unable to locate 15 percent of the 693 sons whose whereabouts had ever been known since birth; 26 others (4 percent) had died, and 12 (2 percent) had requested that they be excluded from any future follow-up. Of the 548 men we contacted, 1 was incompetent to be interviewed and 53 others (10 percent) declined to participate. Our study group thus consisted of 494 men, who made up 62 percent of the 801 survivors of the original cohort and 74 percent of the 667 men who had not died or been lost to follow-up before 1975 (Table 1).

Of these 494, 365 (74 percent) reported that they had ever impregnated a woman. We requested permission to contact the female partner who had most recently become pregnant, so that we could collect more detailed information about that pregnancy. The partner's name and telephone number were provided by 312 men (85 percent). Of those women, 305 (98 percent) consented to be interviewed.

Trained female interviewers carried out structured telephone interviews with the men and their female partners. Fifty-one percent of the men still lived in Illinois; the remainder lived in 39 other states and 8 foreign countries. The exposure status of the men was not known to the interviewers. Interviews with the men and their partners lasted an average of 25 and 20 minutes, respectively.

The length of time to conception in the most recent pregnancy was analyzed with use of a discrete-time analogue of the Cox proportional-hazards model.13 Confidence intervals for differences in percentages were based on binomial standard errors.

Results

We interviewed 494 men (253 who were exposed to diethylstilbestrol prenatally and 241 who were not exposed), all between the ages of 38 and 41 years. These men represented 64 percent of the surviving males of the original University of Chicago cohort who were exposed in utero and 59 percent of the unexposed males. The large number of sons lost to follow-up between 1952 and 1992 (26 percent of the exposed males and 31 percent of the unexposed males) raises the possibility of selection bias among those who actually participated. To address this question, we compared the men who participated in our study with all the rest of the original group. No differences were found in their mothers' mean age at delivery or in the week of pregnancy during which diethylstilbestrol treatment was begun.

In order to pursue the possibility that some unknown factor differentially influenced the entry of exposed and unexposed men into our study, we compared the biologic and demographic characteristics of the exposed and unexposed men. The two groups were nearly identical in height, weight, education, income, race or ethnic group, smoking status, and age at first marriage. The men exposed to diethylstilbestrol were slightly more likely than the unexposed men to be married at the time of the interview (75 percent vs. 69 percent, P = 0.12).

We assessed differences between the exposed and unexposed men that might affect their fertility. Twelve percent of the men in each group reported that they had at some time been given a diagnosis of a sexually transmitted disease. However, the men exposed to diethylstilbestrol reported substantially more medically diagnosed genital malformations (15 percent, vs. 5 percent among the unexposed men; P<0.01). The most common malformations in these men were epididymal cysts and hypoplastic testes, described in previous reports of the clinical examination of men from this cohort.9,13

We further divided the exposed men into two groups: those whose mothers' diethylstilbestrol treatment had started within 10 weeks and 6 days of their last menstrual periods, and those whose treatment started at 11 completed weeks of gestation or later. The prevalence of reported malformations was twice as high among the men with early exposure as among those whose exposure began later (P = 0.05) (Table 2Table 2Reported Genital Abnormalities According to Diethylstilbestrol-Exposure Status and Timing of Diethylstilbestrol Treatment.). Even so, men with malformations of the genitalia were no different from all the other men in the percentage who had ever fathered a child, the age at the birth of their first child, the total number of children, or any other measure of fertility.

Finally, we compared all the exposed and unexposed men (regardless of the presence or absence of malformations) in terms of a variety of end points related to fertility (Table 3Table 3Fertility-Related End Points among Men Exposed Prenatally to Diethylstilbestrol and Unexposed Men.). The reported rate of physical development during adolescence, age at first intercourse, frequency of intercourse, and sexual activity with male partners were similar in the two groups. The diethylstilbestrol-exposed men were more often concerned about possible infertility than the unexposed men and were slightly more likely to have sought medical advice because of problems with fertility. However, an actual medical diagnosis of male infertility was reported no more often by exposed than by unexposed men.

Other problems related to infertility were actually less common among the men exposed to diethylstilbestrol. Fewer of the exposed men reported being childless, and fewer reported that it had taken more than a year for their partners to achieve pregnancy, that they had ever sought medical treatment for problems of erection or ejaculation, or that they had had decreased sex drive for at least three months. Conception while using birth control is an indirect measure of a couple's fertility; thus, the more fertile the couple the more likely they are to conceive accidentally. There were more exposed men than unexposed men who reported pregnancies conceived while they were using some method of birth control.

A sensitive measure of a couple's fertility is the length of time to conception — that is, the number of menstrual cycles from the time the couple stops using contraception until conception occurs.13 Of the 305 women we interviewed, 82 (30 percent of the partners of exposed men and 21 percent of the partners of unexposed men) were unable to give useful data on the length of time to their most recent pregnancies because the pregnancies had been unplanned or the use of birth control had been sporadic. The remaining 223 women (119 partners of exposed men and 104 partners of unexposed men) provided usable information. Figure 1Figure 1Cumulative Probability of Conception per Menstrual Cycle for 119 Couples in Which the Man Was Exposed Prenatally to Diethylstilbestrol and 104 Couples in Which the Man Was Unexposed. shows the cumulative percentage of the group that was pregnant at each cycle after the discontinuation of birth-control measures. No difference between the partners of the exposed and those of the unexposed men is apparent.

The length of time to conception can be adjusted for possible confounding factors by expressing the outcome in terms of fecundability (the chance of conception per menstrual cycle).14 When the fecundability of exposed and unexposed couples is compared as a ratio, a value of less than 1 indicates lower fertility among the exposed men and their partners. The fecundability ratio was slightly but not significantly lower for the exposed men (0.9; 95 percent confidence interval, 0.7 to 1.2). We adjusted this ratio for possible confounding by the frequency of intercourse, alcohol consumption or smoking by the man or his partner, caffeine consumption by the partner, and other factors. The resulting fecundability ratio was unchanged (0.9; 95 percent confidence interval, 0.7 to 1.1). Among exposed men, the timing of the first exposure to diethylstilbestrol had no effect on fecundability. Finally, fecundability was not reduced in men with malformations of the genitalia, regardless of their exposure status.

Discussion

The effects of diethylstilbestrol on the human fetus might have gone unnoticed had there not been an extraordinarily strong association of diethylstilbestrol with a rare vaginal tumor.2 This fact called attention to the broader consequences of prenatal exposure to diethylstilbestrol, particularly its potential effects on the reproductive systems of both sexes.

Studies in Animals

Much of our understanding of the effects of prenatal exposure to diethylstilbestrol has come from studies of rodents. Mice are exquisitely sensitive to the prenatal effects of diethylstilbestrol; female mice are rendered virtually sterile at weight-adjusted concentrations of diethylstilbestrol only 5 percent of the average dose received by women in the University of Chicago clinical trial.6

Diethylstilbestrol also impairs fertility in male mice. However, the effect of diethylstilbestrol in males does not follow the steady dose–response pattern seen in females; instead, the effect is found only above a relatively high threshold level of diethylstilbestrol.6 Impaired fertility appears to be secondary to retained testes and other gross anatomical disruptions of the male reproductive system.6

Genital Malformations

Diethylstilbestrol-related malformations of the reproductive tract have been reported in both men and women.8,15 Men exposed prenatally to diethylstilbestrol reported more malformations of the genitalia than unexposed men in our study, as would be expected from the results of their clinical examinations in the 1970s.8,12

Previous studies of the Chicago cohort did not consider the influence of the timing of exposure on malformations in males. Our data suggest that the risk of genital malformation is higher among men who were exposed relatively early in gestation. Adult men are presumably unaware of the week of gestation during which their mothers' treatment began, so reporting bias is unlikely to account for this association. The higher risk of malformation with exposure to diethylstilbestrol in the first 10 weeks and 6 days after the last menstrual period is consistent with the timing of embryogenesis. The external genitalia have passed their period of highest susceptibility to teratogens by the end of the 9th week of embryonic life (a date corresponding approximately to 11 weeks after the last menstrual period).16

Fertility

Effects of prenatal exposure to diethylstilbestrol on women's fertility have been reported, although not consistently. In the Chicago cohort, primary infertility was more than twice as common among the daughters of women given diethylstilbestrol during pregnancy as among the unexposed daughters.3 No excess infertility was reported in another group of women exposed in utero for whom doses were not as well documented; many may have been exposed to lower doses or had their initial exposure later in gestation.17

The existence of diethylstilbestrol-induced infertility among the sons of women treated with this drug during pregnancy has been widely conjectured.18-20 Such an effect is not implausible, given the infertility seen in studies of rodents7 and the excess rate of minor genitourinary malformations and changes in sperm reported among diethylstilbestrol-exposed men.12 An apparent decrease in penetration of zona-free hamster eggs by sperm from men exposed prenatally to diethylstilbestrol was reported in 1981,10 but in a larger study the same authors were unable to confirm this finding.21 In 1984, investigators from the Mayo Clinic reported that they found no effects of diethylstilbestrol on male fertility.22 The data were inconclusive, however, since the ages of the men were not reported, data on fertility were scant, and the dose of diethylstilbestrol given to the mothers of the men in the study was a small fraction of that received by the mothers in the Chicago cohort (mean cumulative dose, 1430 mg). Other studies have suggested that exposed men have infertility problems, but their results have been based on preliminary data on young men or on small samples.8,9

In our survey of nearly 500 exposed and unexposed men, we found no evidence that diethylstilbestrol impairs male fertility. The men exposed to diethylstilbestrol in utero reported a general concern about their fertility, which is understandable given their knowledge of their own exposure to the drug. However, specific fertility-related difficulties were no more common (and sometimes less common) among the diethylstilbestrol-exposed men than among the unexposed men. Among the subgroups of men for whom we were able to measure the length of time to conception in a female partner, fecundability was apparently unaffected either by exposure of the male partner to diethylstilbestrol or by the presence of male genital malformations.

It has been speculated that prenatal exposure to diethylstilbestrol alters sexual orientation,23 which could affect measures of fertility. In the present study, the overall percentage of men who reported ever having a male sex partner in adulthood was 3 percent, which is consistent with the results of a recent U.S. survey of male sexual behavior.24 Diethylstilbestrol-exposed men and unexposed men were no different in this regard.

The chief strengths of this study derive from its origins in a clinical trial. Diethylstilbestrol treatment (or receipt of placebo) was documented for every mother in the original study, and the randomized, double-blind, placebo-controlled design provided a suitable comparison group in the sons of the women given placebo. Also, the men exposed to diethylstilbestrol whom we surveyed were old enough to have completed a substantial portion of their reproductive lives and thus were able to provide relatively complete data on their fertility.

The chief weakness of the study lies in its incomplete follow-up data. Of the male children of women in the study, 18 percent of both the exposed group and the unexposed group had died by 1992 or were never located after birth. The percentage of men who died or were lost to follow-up after the clinical examinations in the mid-1970s was 18 percent for the exposed group and 20 percent for the unexposed group. Missing data may have distorted the results if the characteristics of the missing men differed from those of the men we studied in terms of exposure to diethylstilbestrol. We have little information about the missing men and so cannot evaluate this issue directly.

Indirectly, we can infer that the effects of this source of bias may be limited, for several reasons. First, the percentage of men lost to follow-up was similar for the exposed and unexposed groups. Second, a comparison of the background characteristics of the exposed and unexposed men in the study provided no evidence that differential selection distorted the composition of the two groups. Moreover, the usual epidemiologic concern is that persons with a health problem may be more likely to volunteer for a study if they know they have been exposed than if they are unexposed. The possibility of response bias would have to be considered if there had been an association of infertility with diethylstilbestrol. With no observed differences in fertility between the exposed and unexposed men, response bias is unlikely.

We found no evidence that diethylstilbestrol has impaired the fertility of men prenatally exposed to the drug. The apparent inconsistency between this result and the results of earlier studies bears closer inspection. Differences in semen measures do not necessarily mean differences in fertility. There could be subtle abnormalities of testicular function caused by diethylstilbestrol that have no effect on a man's fertility. The minor anomalies of the genital tract reported by these men are apparently compatible with full fertility. Moreover, studies of rodents suggest that diethylstilbestrol impairs male fertility but that the effect on male fertility is not as strong as that on female fertility.6 Thus, it is plausible that diethylstilbestrol could affect the fertility of the daughters of the women in the Chicago cohort but not that of the sons. Finally, since the analysis of the length of time to conception was applied only to the most recent pregnancies in the men's female partners, we cannot rule out the possibility that small decrements in fertility could have been present among the exposed men at younger ages, which then resolved with time. Such resolution over time has been suggested for certain diethylstilbestrol-related abnormalities of the female vaginal canal25 and has been reported for abnormalities of the male reproductive tract in a small study of monkeys.26 Still, the men's similar ages at the births of their first children would tend not to support differences in fertility even at younger ages.

The mothers in the Chicago study received a standard dose of diethylstilbestrol, but one that is higher than that used by many clinicians.11,27 The absence of detectable effects on fertility in men exposed prenatally to these high doses should reassure all sons of women treated with diethylstilbestrol. However, our data do not address any health effects of diethylstilbestrol that might emerge at older ages.

We are indebted to Joy Pierce, who directed the field study, and Dr. Jennifer Ratcliffe for assistance in the development of the questionnaire; to Keith Frey, Diane Anderson, Nana Biney, and Nancy Bayless for assistance in the preparation and analysis of the data; to Retha Newbold for helpful suggestions on the interpretation of the literature on studies in animals; and to Drs. Glinda Cooper, Freja Kamel, Andrew Rowland, Dale Sandler, and Shanna Swan for their useful comments on previous versions of this paper.

Source Information

From the Epidemiology Branch (A.J.W., D.D.B.) and the Statistics and Biomathematics Branch (C.R.W.), National Institute of Environmental Health Sciences, Research Triangle Park, N.C.; the Health Sciences Center, University of Virginia, Charlottesville (P.P.H.); and the Department of Obstetrics and Gynecology, University of Chicago, Chicago (A.L.H.).

Address reprint requests to Dr. Wilcox at the Epidemiology Branch, NIEHS, Research Triangle Park, NC 27709.

References

References

  1. 1

    Shapiro S, Slone D. The effects of exogenous female hormones on the fetus. Epidemiol Rev 1979;1:110-123
    Medline

  2. 2

    Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878-881
    Full Text | Web of Science | Medline

  3. 3

    Senekjian EK, Potkul RK, Frey K, Herbst AL. Infertility among daughters either exposed or not exposed to diethylstilbestrol. Am J Obstet Gynecol 1988;158:493-498
    Web of Science | Medline

  4. 4

    Herbst AL, Senekjian EK, Frey K. Abortion and pregnancy loss among diethylstilbestrol-exposed women. Semin Reprod Endocrinol 1989;7:124-129
    CrossRef

  5. 5

    McLachlan JA, Newbold RR, Bullock B. Reproductive tract lesions in male mice exposed prenatally to diethylstilbestrol. Science 1975;190:991-992
    CrossRef | Web of Science | Medline

  6. 6

    McLachlan JA. Prenatal exposure to diethylstilbestrol in mice: toxicological studies. J Toxicol Environ Health 1977;2:527-537
    CrossRef | Medline

  7. 7

    McLachlan JA. Rodent models for perinatal exposure to diethylstilbestrol and their relation to human disease in the male. In: Herbst AL, Bern HA, eds. Developmental effects of diethylstilbestrol (DES) in pregnancy. New York: Thieme-Stratton, 1981:148-57.

  8. 8

    Gill WB. Effects on human males of in utero exposure to exogenous sex hormones. In: Mori T, Nagasawa H, eds. Toxicity of hormones in perinatal life. Boca Raton, Fla.: CRC Press, 1989:161-77.

  9. 9

    Beral V, Colwell L. Randomized trial of high doses of stilboestrol and ethisterone therapy in pregnancy: long-term follow-up of the children. J Epidemiol Community Health 1981;35:155-160
    CrossRef | Web of Science | Medline

  10. 10

    Stenchever MA, Williamson RA, Leonard J, et al. Possible relationship between in utero diethylstilbestrol exposure and male fertility. Am J Obstet Gynecol 1981;140:186-193
    Web of Science | Medline

  11. 11

    Dieckmann WJ, Davis ME, Rynkiewicz LM, Pottinger RE. Does the administration of diethylstilbestrol during pregnancy have therapeutic value? Am J Obstet Gynecol 1953;66:1062-1081
    Web of Science | Medline

  12. 12

    Gill WB, Schumacher GFB, Bibbo M, Straus FH II, Schoenberg HW. Association of diethylstilbestrol exposure in utero with cryptorchidism, testicular hypoplasia and semen abnormalities. J Urol 1979;122:36-39
    Web of Science | Medline

  13. 13

    Baird DD, Wilcox AJ, Weinberg CR. Use of time to pregnancy to study environmental exposures. Am J Epidemiol 1986;124:470-480
    Web of Science | Medline

  14. 14

    Weinberg CR, Baird DD, Wilcox AJ. Sources of bias in studies of time to pregnancy. Stat Med 1994;13:671-681
    CrossRef | Web of Science | Medline

  15. 15

    Kaufman RH, Binder GL, Gray PM Jr, Adam E. Upper genital tract changes associated with exposure in utero to diethylstilbestrol. Am J Obstet Gynecol 1977;128:51-59
    Web of Science | Medline

  16. 16

    Moore KL, Persaud TVN. The developing human: clinically oriented embryology. 5th ed. Philadelphia: W.B. Saunders, 1993:156.

  17. 17

    Barnes AB, Colton T, Gundersen J, et al. Fertility and outcome of pregnancy in women exposed in utero to diethylstilbestrol. N Engl J Med 1980;302:609-613
    Full Text | Web of Science | Medline

  18. 18

    Stillman RJ. In utero exposure to diethylstilbestrol: adverse effects on the reproductive tract and reproductive performance in male and female offspring. Am J Obstet Gynecol 1982;142:905-921
    Web of Science | Medline

  19. 19

    Arai Y, Mori T, Suzuki Y, Bern H. Long-term effects of perinatal exposure to sex steroids and diethylstilbestrol on the reproductive system of male mammals. Int Rev Cytol 1983;84:235-268
    CrossRef | Web of Science | Medline

  20. 20

    Newkirk P. A mother's nightmare: the shocking story of diethylstilbestrol sons. McCall's. February 1993:93, 164.

  21. 21

    Shy KK, Stenchever MA, Karp LE, Berger RE, Williamson RA, Leonard J. Genital tract examinations and zona-free hamster egg penetration tests from men exposed in utero to diethylstilbestrol. Fertil Steril 1984;42:772-778
    Web of Science | Medline

  22. 22

    Leary FJ, Ressiguie LJ, Kurland LT, O'Brien PC, Emslander RF, Noller KL. Males exposed in utero to diethylstilbestrol. JAMA 1984;252:2984-2989
    CrossRef | Web of Science | Medline

  23. 23

    Meyer-Bahlburg HF. Psychoendocrine research on sexual orientation: current status and future options. Prog Brain Res 1984;61:375-398
    CrossRef | Web of Science | Medline

  24. 24

    Billy JOG, Tanfer K, Grady WR, Klepinger DH. The sexual behavior of men in the United States. Fam Plann Perspect 1993;25:52-60
    CrossRef | Medline

  25. 25

    Herbst AL, Hubby MM, Azizi F, Makii MM. Reproductive and gynecologic surgical experience in diethylstilbestrol-exposed daughters. Am J Obstet Gynecol 1981;144:1019-1028

  26. 26

    Thompson RS, Hess DL, Binkerd PE, Hendrickx AG. The effects of prenatal diethylstilbestrol exposure on the genitalia of pubertal Macaca mulatta. II. Male offspring. J Reprod Med 1981;26:309-316
    Web of Science | Medline

  27. 27

    Herbst AL, Kurman RJ, Scully RE, Poskanzer DC. Clear-cell adenocarcinoma of the genital tract in young females: registry report. N Engl J Med 1972;287:1259-1264
    Full Text | Web of Science | Medline

Citing Articles (76)

Citing Articles

  1. 1

    Nicolas Kalfa, Françoise Paris, Marie-Odile Soyer-Gobillard, Jean-Pierre Daures, Charles Sultan. (2011) Prevalence of hypospadias in grandsons of women exposed to diethylstilbestrol during pregnancy: a multigenerational national cohort study. Fertility and Sterility 95:8, 2574-2577
    CrossRef

  2. 2

    A.W.F.T. Toorians, T.F.H. Bovee, J. De Rooy, L.A.A.M. Stolker, R.L.A.P. Hoogenboom. (2010) Gynaecomastia linked to the intake of a herbal supplement fortified with diethylstilbestrol. Food Additives & Contaminants: Part A 27:7, 917-925
    CrossRef

  3. 3

    L. Titus-Ernstoff, R. Troisi, E. E. Hatch, J. R. Palmer, M. Hyer, R. Kaufman, E. Adam, K. Noller, R. N. Hoover. (2010) Birth defects in the sons and daughters of women who were exposed in utero to diethylstilbestrol (DES). International Journal of Andrology 33:2, 377-384
    CrossRef

  4. 4

    M. Joffe. (2010) What has happened to human fertility?. Human Reproduction 25:2, 295-307
    CrossRef

  5. 5

    David J. Handelsman, Trevor G. Cooper. (2010) Afterword to Semen Analysis in 21st Century Medicine special issue in Asian Journal of Andrology. Asian Journal of Andrology 12:1, 118-123
    CrossRef

  6. 6

    O. Akre, L. Richiardi. (2009) Does a testicular dysgenesis syndrome exist?. Human Reproduction 24:9, 2053-2060
    CrossRef

  7. 7

    Takashi Miyakoshi, Katsuhiro Miyajima, Susumu Takekoshi, Robert Yoshiyuki Osamura. (2009) The Influence of Endocrine Disrupting Chemicals on the Proliferation of ERα Knockdown-Human Breast Cancer Cell Line MCF-7; New Attempts by RNAi Technology. ACTA HISTOCHEMICA ET CYTOCHEMICA 42:2, 23-28
    CrossRef

  8. 8

    Michael Garner, Michelle C. Turner, Parviz Ghadirian, Daniel Krewski, Michael Wade. (2008) Testicular Cancer and Hormonally Active Agents. Journal of Toxicology and Environmental Health, Part B 11:3-4, 260-275
    CrossRef

  9. 9

    Fariba Salehi, Lesley Dunfield, Karen P. Phillips, Daniel Krewski, Barbara C. Vanderhyden. (2008) Risk Factors for Ovarian Cancer: An Overview with Emphasis on Hormonal Factors. Journal of Toxicology and Environmental Health, Part B 11:3-4, 301-321
    CrossRef

  10. 10

    Linda Titus-Ernstoff, Rebecca Troisi, Elizabeth E. Hatch, Marianne Hyer, Lauren A. Wise, Julie R. Palmer, Raymond Kaufman, Ervin Adam, Kenneth Noller, Arthur L. Herbst, William Strohsnitter, Bernard F. Cole, Patricia Hartge, Robert N. Hoover. (2008) Offspring of Women Exposed In Utero to Diethylstilbestrol (DES). Epidemiology 19:2, 251-257
    CrossRef

  11. 11

    Chhanda Gupta. (2008) Reproductive Malformation of the Male Offspring Following Maternal Exposure to Estrogenic Chemicals. Proceedings of the Society for Experimental Biology and Medicine 224:2, 61
    CrossRef

  12. 12

    Jonathan P. Jarow. (2007) Diagnostic Approach to the Infertile Male Patient. Endocrinology & Metabolism Clinics of North America 36:2, 297-311
    CrossRef

  13. 13

    Ruby H.N. Nguyen, Allen J. Wilcox, Donna D. Baird. (2007) Can Men Provide Accurate Confounder Data About their Partners for Time-to-Pregnancy Studies?. Annals of Epidemiology 17:3, 186-190
    CrossRef

  14. 14

    Vu Hoang Dang, Kyung-Chul Choi, Sang-Hwan Hyun, Eui-Bae Jeung. (2007) Analysis of gene expression profiles in the offspring of rats following maternal exposure to xenoestrogens. Reproductive Toxicology 23:1, 42-54
    CrossRef

  15. 15

    M. Chalubinski, M. L. Kowalski. (2006) Endocrine disrupters – potential modulators of the immune system and allergic response. Allergy 61:11, 1326-1335
    CrossRef

  16. 16

    Lone Storgaard, Jens Peter Bonde, Jørn Olsen. (2006) Male reproductive disorders in humans and prenatal indicators of estrogen exposure. Reproductive Toxicology 21:1, 4-15
    CrossRef

  17. 17

    Andrea M Isidori, Carlotta Pozza, Daniele Gianfrilli, Aldo Isidori. (2006) Medical treatment to improve sperm quality. Reproductive BioMedicine Online 12:6, 704-714
    CrossRef

  18. 18

    Kimberly M. Perez, Linda Titus-Ernstoff, Elizabeth E. Hatch, Rebecca Troisi, Jean Wactawski-Wende, Julie R. Palmer, Kenneth Noller, Robert N. Hoover. (2005) Reproductive outcomes in men with prenatal exposure to diethylstilbestrol. Fertility and Sterility 84:6, 1649-1656
    CrossRef

  19. 19

    Ruby H. N. Nguyen, Donna D. Baird. (2005) Accuracy of Men??s Recall of Their Partner??s Time to Pregnancy. Epidemiology 16:5, 694-698
    CrossRef

  20. 20

    Julie R. Palmer, Lauren A. Wise, Stanley J. Robboy, Linda Titus-Ernstoff, Kenneth L. Noller, Arthur L. Herbst, Rebecca Troisi, Robert N. Hoover. (2005) Hypospadias in Sons of Women Exposed to Diethylstilbestrol In Utero. Epidemiology 16:4, 583-586
    CrossRef

  21. 21

    Marieke Veurink, Marlies Koster, Lolkje T.W. de Jong-van den. Berg. (2005) The History of DES, Lessons to be Learned. Pharmacy World & Science 27:3, 139-143
    CrossRef

  22. 22

    Stephen Safe. (2005) Clinical correlates of environmental endocrine disruptors. Trends in Endocrinology & Metabolism 16:4, 139-144
    CrossRef

  23. 23

    Vincenzo Rochira, Antonio R M Granata, Bruno Madeo, Lucia Zirilli, Giuseppina Rossi, Cesare Carani. (2005) Estrogens in males: what have we learned in the last 10 years?. Asian Journal of Andrology 7:1, 3-20
    CrossRef

  24. 24

    Robert Golden, Jay Gandy, Guenter Vollmer. (2005) A Review of the Endocrine Activity of Parabens and Implications for Potential Risks to Human Health. Critical Reviews in Toxicology 35:5, 435-458
    CrossRef

  25. 25

    Eui-Ju HONG, Youn-Kyu JI, Kyung-Chul CHOI, Noboru MANABE, Eui-Bae JEUNG. (2005) Conflict of Estrogenic Activity by Various Phthalates between In Vitro and In Vivo Models Related to the Expression of Calbindin-D9k. Journal of Reproduction and Development 51:2, 253-263
    CrossRef

  26. 26

    Christoph Dorn, Hans van der Ven. (2005) Clomiphene citrate versus gonadotrophins for ovulation stimulation. Reproductive BioMedicine Online 10, 37-43
    CrossRef

  27. 27

    Stephen Safe. (2004) Endocrine disruptors and human health: is there a problem. Toxicology 205:1-2, 3-10
    CrossRef

  28. 28

    Minerva Mercado-Feliciano, Josephine Mubiru, Robert Bigsby. 2004. Molecular Mechanisms of Endocrine Disruption in Estrogen Dependent Processes. , 217-247.
    CrossRef

  29. 29

    SriTulasi Karri, Heather Johnson, William J. Hendry, Simon C. Williams, Shafiq A. Khan. (2004) Neonatal exposure to diethylstilbestrol leads to impaired action of androgens in adult male hamsters. Reproductive Toxicology 19:1, 53-63
    CrossRef

  30. 30

    George M. Gray, Joshua T. Cohen, Gerald Cunha, Claude Hughes, Ernest E. McConnell, Lorenz Rhomberg, I. Glenn Sipes, Donald Mattison. (2004) Weight of the Evidence Evaluation of Low-Dose Reproductive and Developmental Effects of Bisphenol A. Human and Ecological Risk Assessment: An International Journal 10:5, 875-921
    CrossRef

  31. 31

    Retha R Newbold. (2004) Lessons learned from perinatal exposure to diethylstilbestrol. Toxicology and Applied Pharmacology 199:2, 142-150
    CrossRef

  32. 32

    Eui-Ju Hong, Kyung-Chul Choi, Yong-Woo Jung, Peter C.K Leung, Eui-Bae Jeung. (2004) Transfer of maternally injected endocrine disruptors through breast milk during lactation induces neonatal Calbindin-D9k in the rat model. Reproductive Toxicology 18:5, 661-668
    CrossRef

  33. 33

    H.O Goyal, T.D Braden, C.S Williams, P Dalvi, J.W Williams, K.K Srivastava. (2004) Exposure of neonatal male rats to estrogen induces abnormal morphology of the penis and loss of fertility. Reproductive Toxicology 18:2, 265-274
    CrossRef

  34. 34

    Eui-Ju Hong, Kyung-Chul Choi, Eui-Bae Jeung. (2003) Maternal-fetal transfer of endocrine disruptors in the induction of Calbindin-D9k mRNA and protein during pregnancy in rat model. Molecular and Cellular Endocrinology 212:1-2, 63-72
    CrossRef

  35. 35

    Anthony A Bamigboye, Jonathan Morris, Anthony A Bamigboye. 2003. Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes. .
    CrossRef

  36. 36

    Kelly Kruse, Diane Lauver, Karen Hanson. (2003) Clinical Implications of DES. The Nurse Practitioner 28:7, 26-35
    CrossRef

  37. 37

    Linda Titus-Ernstoff, Kimberly Perez, Elizabeth E. Hatch, Rebecca Troisi, Julie R. Palmer, Patricia Hartge, Marianne Hyer, Raymond Kaufman, Ervin Adam, William Strohsnitter, Kenneth Noller, Kate E. Pickett, Robert Hoover. (2003) Psychosexual Characteristics of Men and Women Exposed Prenatally to Diethylstilbestrol. Epidemiology 14:2, 155-160
    CrossRef

  38. 38

    Richard M. Sharpe. (2003) The 'oestrogen hypothesis'- where do we stand now?1. International Journal of Andrology 26:1, 2-15
    CrossRef

  39. 39

    Peter J. Burrows, Christopher G. Schrepferman, Larry I. Lipshultz. (2002) Comprehensive office evaluation in the new millennium. Urologic Clinics of North America 29:4, 873-894
    CrossRef

  40. 40

    Masahiro Kuwada, Rei Kawashima, Kazuo Nakamura, Hisako Kojima, Hideyo Hasumi, Jun Maki, Sachiko Sugano. (2002) Neonatal exposure to endocrine disruptors suppresses juvenile testis weight and steroidogenesis but spermatogenesis is considerably restored during puberty. Biochemical and Biophysical Research Communications 295:1, 193-197
    CrossRef

  41. 41

    J.J. Amaral Mendes. (2002) The endocrine disrupters: a major medical challenge. Food and Chemical Toxicology 40:6, 781-788
    CrossRef

  42. 42

    Ida Norgil Damgaard, Katharina Maria Main, Jorma Toppari, Niels E. Skakkebæk. (2002) Impact of exposure to endocrine disrupters inutero and in childhood on adult reproduction. Best Practice & Research Clinical Endocrinology & Metabolism 16:2, 289-309
    CrossRef

  43. 43

    Sonia Hernández-Díaz. (2002) Iatrogenic legacy from diethylstilbestrol exposure. The Lancet 359:9312, 1081-1082
    CrossRef

  44. 44

    Majken Dalgaard, Kirsten Pilegaard, Ole Ladefoged. (2002) In Utero Exposure to Diethylstilboestrol or 4-n-Nonylphenol in Rats: Number of Sertoli Cells, Diameter and Length of Seminiferous Tubules Estimated by Stereological Methods. Pharmacology and Toxicology 90:2, 59-65
    CrossRef

  45. 45

    R.F.A. Weber, F.H. Pierik, G.R. Dohle, A. Burdorf. (2002) Environmental influences on male reproduction. BJU International 89:2, 143-148
    CrossRef

  46. 46

    JOHN A. McLACHLAN, RETHA R. NEWBOLD, MATTHEW E. BUROW, SHUAN FANG LI. (2001) From malformations to molecular mechanisms in the male: three decades of research on endocrine disrupters. APMIS 109:S103, S1-S11
    CrossRef

  47. 47

    K.A. Thayer, R.L. Ruhlen, K.L. Howdeshell, D.L. Buchanan, P.S. Cooke, D. Preziosi, W.V. Welshons, J. Haseman, F.S. Saal. (2001) Altered prostate growth and daily sperm production in male mice exposed prenatally to subclinical doses of 17α-ethinyl oestradiol. APMIS 109:S103, S278-S288
    CrossRef

  48. 48

    S. H. SWAN. (2001) Intrauterine exposure to diethylstilbestrol: Long-term effects in humans. APMIS 109:S103, S210-S222
    CrossRef

  49. 49

    RETHA R. NEWBOLD. (2001) Effects of developmental exposure to diethylstilbestrol (DES) in rodents: clues for other environmental estrogens. APMIS 109:S103, S261-S271
    CrossRef

  50. 50

    Carole A. Kimmel, Judy Buelke-Sam. 2001. Reproductive and Developmental Toxicology. .
    CrossRef

  51. 51

    W. C. Strohsnitter, K. L. Noller, R. N. Hoover, S. J. Robboy, J. R. Palmer, L. Titus-Ernstoff, R. H. Kaufman, E. Adam, A. L. Herbst, E. E. Hatch. (2001) Cancer Risk in Men Exposed In Utero to Diethylstilbestrol. JNCI Journal of the National Cancer Institute 93:7, 545-551
    CrossRef

  52. 52

    S. H. SWAN. (2000) Intrauterine exposure to diethylstilbestrol: Long-term effects in humans. APMIS 108:12, 793-804
    CrossRef

  53. 53

    Harry Fisch, Grace Hyun, Robert Golden. (2000) The possible effects of environmental estrogen disrupters on reproductive health. Current Urology Reports 1:4, 253-261
    CrossRef

  54. 54

    L. Bujan. (2000) Environnement et Spermatogenèse. Andrologie 10:3, 254-270
    CrossRef

  55. 55

    D. S. Irvine. (2000) Male reproductive health: cause for concern?. Andrologia 32:4-5, 195-208
    CrossRef

  56. 56

    JOrn Olsen, Jens Peter Bonde, Olga Basso, Niels Henrik I. Hjollund, Henrik Toft SOrensen, Annette Abell. (2000) Birthweight and semen characteristics. International Journal of Andrology 23:4, 230-235
    CrossRef

  57. 57

    Chhanda Gupta. (2000) Reproductive Malformation of the Male Offspring Following Maternal Exposure to Estrogenic Chemicals. Proceedings of the Society for Experimental Biology and Medicine 224:2, 61-68
    CrossRef

  58. 58

    Stephen H. Safe. (2000) Endocrine Disruptors and Human Health--Is There a Problem? An Update. Environmental Health Perspectives 108:6, 487-493
    CrossRef

  59. 59

    Arthur L. Herbst, Howard Ulfelder, David C. Poskanzer. (1999) Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. American Journal of Obstetrics and Gynecology 181:6, 1574-1575
    CrossRef

  60. 60

    Susan Barlow, Robert J. Kavlock, John A. Moore, Susan L. Schantz, Daniel M. Sheehan, Dana L. Shuey, Joseph M. Lary. (1999) Teratology society public affairs committee position paper: Developmental toxicity of endocrine disruptors to humans. Teratology 60:6, 365-375
    CrossRef

  61. 61

    Toshihiro Takao, Wakako Nanamiya, Isao Nagano, Koichi Asaba, Kenji Kawabata, Kozo Hashimoto. (1999) Exposure with the environmental estrogen bisphenol a disrupts the male reproductive tract in young mice. Life Sciences 65:22, 2351-2357
    CrossRef

  62. 62

    Cesare Carani, Vincenzo Rochira, Marco Faustini-Fustini, Antonio Balestrieri, Granata. (1999) Role of oestrogen in male sexual behaviour: insights from the natural model of aromatase deficiency. Clinical Endocrinology 51:4, 517-524
    CrossRef

  63. 63

    Elina Hemminki, Mika Gissler, Jouni Meriläinen. (1999) Reproductive effects of in utero exposure to estrogen and progestin drugs. Fertility and Sterility 71:6, 1092-1098
    CrossRef

  64. 64

    NIELS E. SKAKKEBÉK, EWA RAJPERT-DE MEYTS, NIELS JØRGENSEN, ELISABETH CARLSEN, PETER MEIDAHL PETERSEN, ALEKSANDER GIWERCMAN, ANNE-GRETHE ANDERSEN, TINA KOLD JENSEN, ANNA-MARIA ANDERSSON, JØRN MÜLLER. (1998) Germ cell cancer and disorders of spermatogenesis: An environmental connection?. APMIS 106:1-6, 3-12
    CrossRef

  65. 65

    Bradley E. Gillesby, Timothy R. Zacharewski. (1998) Exoestrogens: Mechanisms of action and strategies for identification and assessment. Environmental Toxicology and Chemistry 17:1, 3-14
    CrossRef

  66. 66

    Jack B. Bishop, Kristine L. Witt, Richard A. Sloane. (1997) Genetic toxicities of human teratogens. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 396:1-2, 9-43
    CrossRef

  67. 67

    P.T.C. Harrison, P. Holmes, C.D.N. Humfrey. (1997) Reproductive health in humans and wildlife: are adverse trends associated with environmental chemical exposure?. Science of The Total Environment 205:2-3, 97-106
    CrossRef

  68. 68

    Paul M. Vancutsem, Michele L. Roessler. (1997) Neonatal treatment with tamoxifen causes immediate alterations of the sexually dimorphic nucleus of the preoptic area and medial preoptic area in male rats. Teratology 56:3, 220-228
    CrossRef

  69. 69

    D Lamb. (1997) Hormonal Disruptors and Male Infertility: Are Men at Serious Risk?,. Regulatory Toxicology and Pharmacology 26:1, 30-33
    CrossRef

  70. 70

    George P Daston, Jay W Gooch, William J Breslin, Dana L Shuey, Andrey I Nikiforov, Theresa A Fico, Joseph W Gorsuch. (1997) Environmental estrogens and reproductive health: A discussion of the human and environmental data. Reproductive Toxicology 11:4, 465-481
    CrossRef

  71. 71

    Margret Schlumpf, Walter Lichtensteiger. (1996) Hormonaktive Xenobiotika. Umweltwissenschaften und Schadstoff-Forschung 8:6, 321-332
    CrossRef

  72. 72

    Robert J. Kavlock, Gerald T. Ankley. (1996) A Perspective on the Risk Assessment Process for Endocrine-Disruptive Effects on Wildlife and Human Health*. Risk Analysis 16:6, 731-739
    CrossRef

  73. 73

    Hasso Seibert. (1996) Störungen der Entwicklung und Funktion des männlichen Reproduktionssystems. Umweltwissenschaften und Schadstoff-Forschung 8:5, 275-284
    CrossRef

  74. 74

    I. Palmlund. (1996) Exposure to a xenoestrogen before birth: the diethylstilbestrol experience. Journal of Psychosomatic Obstetrics & Gynecology 17:2, 71-84
    CrossRef

  75. 75

    Howard E. Kulin, Niels E. Skakkebaek. (1995) Environmental effects on human reproduction: The basis for new efforts in Eastern Europe. Social Science & Medicine 41:11, 1479-1486
    CrossRef

  76. 76

    James Le Fanu. (1995) Can We Determine What Level of Environmental Toxins Presents a Serious Risk?. Economic Affairs 16:1, 15-18
    CrossRef